AC Immune to Present at the Jefferies 2025 London Healthcare Conference
AC Immune (NASDAQ:ACIU) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $8.00 price target on the stock.
AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
AC Immune Appoints Renowned Neurologist Catherine Mummery as Chair of Clinical Advisory Board
First Characterization of a TDP-43 PET Tracer Published in Nature Communications Showing Potential of AC Immune’s ACI-19626 in Precision Medicine